breast cancer

News

Can new Tukysa data drop unlock its sales potential?

A phase 3 study suggests Pfizer's underperforming HER2 inhibitor Tukysa could play a role in first-line maintenance of HER2-positive breast cancer.

News

Delayed TNBC readout for Datroway delivers survival benefit

AstraZeneca and Daiichi Sankyo's Datroway comes good in the delayed TROPION-Breast02 trial as a frontline triple-negative breast cancer treatment.

News

Enhertu scores again in early breast cancer

AstraZeneca and Daiichi Sankyo are eyeing regulatory filings for Enhertu in early breast cancer after a second phase 3 trial delivers.

News

Lilly brings second oral SERD to market for breast cancer

Lilly's Inluriyo is the second oral SERD to reach the US market for ESR1-mutated breast cancer, setting up a market tussle with Menarini's Orserdu.

News

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.

News

Packets of Verzenio fanned out on display

Lilly raises stakes in Novartis battle with Verzenio data

Armed with new survival data for Verzenio in early breast cancer, Lilly hopes to keep the drug's nose in front of a fast-growing rival from Novartis.

Can new Tukysa data drop unlock its sales potential?

Delayed TNBC readout for Datroway delivers survival benefit

Enhertu scores again in early breast cancer

Lilly brings second oral SERD to market for breast cancer

Roche's oral SERD comes good in 2nd-line breast cancer trial

Lilly raises stakes in Novartis battle with Verzenio data

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

breast cancer

Editor's Picks